Thierry Bordet

Thierry brings more than 18 years of experience in the biotechnology sector, having managed drug discovery and drug development programs for small molecules, gene therapies, cell-based therapies, and regenerative medicine. Earlier in his career, as scientific project leader in drug discovery programs for motor neuron disorders and subsequently as head of CNS pharmacology at Trophos, Thierry played a key role in the identification and preclinical development of olesoxime, the company’s lead compound, which proved to be active in a phase 3 clinical trial for spinal muscular atrophy. After Trophos’ acquisition by Roche, he became the director of preclinical development at the Biotherapies Institute for Rare Diseases in Evry, France, where he conducted development strategies for advanced therapy medicinal products in various indications, including Crigler-Najjar syndrome and retinitis pigmentosa. Thierry is a graduate of École Normale Supérieure de Lyon and holds a PhD in microbiology and virology from Pierre and Marie Curie University (Paris VI).